Mounjaro Health Risks: What the Clinical Evidence Shows

What clinical trials and regulators have established about tirzepatide's risks

The SURMOUNT programme, which enrolled thousands of adults across its trials, generated the safety dataset that underpins Mounjaro's UK licence. The picture that emerged was consistent: the NHS patient information page for tirzepatide summarises the most frequently reported effects as gastrointestinal, nausea, vomiting, diarrhoea, constipation, indigestion and reflux. These are dose-related, meaning they tend to peak when treatment starts at 2.5mg and again with each upward step, then ease as the body adapts. That is not the same as saying they are trivial; for some people they are disruptive enough to require a slower titration, and your prescriber should know about any GI symptoms that persist.

Beyond GI effects, the SURMOUNT-1 trial data (published in the New England Journal of Medicine) and the broader programme recorded injection-site reactions, headache, dizziness, fatigue and (less commonly) hair thinning. If you want a thorough overview before speaking to a prescriber, our dedicated guide to Mounjaro risks covers the full regulatory picture alongside the trial findings. The tirzepatide health risks discussed in formal regulatory review also include gallbladder disease, including gallstones: the licence documentation flags this, and new or worsening upper-right abdominal pain warrants a prompt call to your GP or prescriber. If you're weighing this up honestly, the adverse-event rates in the trials were not zero, but serious events were uncommon and often comparable to those seen with other weight-management medicines.

Mounjaro's Black Triangle designation means the MHRA continues to collect and evaluate real-world safety data beyond what the trials captured. That is a feature of newer medicines in the UK system, not a mark of exceptional concern, but it does reinforce why ongoing clinical oversight matters.

The risks that need urgent medical attention

Some of the health risks of Mounjaro are rare but serious enough that recognising the warning signs early matters. The MHRA's January 2026 Drug Safety Update specifically called out acute pancreatitis: if you develop severe stomach pain that does not ease and spreads to your back (with or without vomiting) stop the injection and seek emergency care. Do not wait to see whether it settles overnight.

Other situations that warrant prompt contact with a doctor or prescriber include signs of a serious allergic reaction (swelling of the face, lips or throat; difficulty breathing; rapidly spreading rash), symptoms of gallbladder problems (sharp pain under the right ribs, fever, yellowing of the skin or eyes), severe dehydration from prolonged vomiting or diarrhoea, and (for anyone also managing diabetes) signs of hypoglycaemia if used alongside insulin or a sulphonylurea. Sudden changes in vision should also be reported, given the known context of diabetic retinopathy in some patients using semaglutide-class medicines.

Mental health is a less-discussed dimension of the tirzepatide health risks picture. If you notice low mood, unusual anxiety or, in particular, thoughts of self-harm, contact a healthcare professional the same day. Our prescribers take these reports seriously, and there is a dedicated guide on Mounjaro and mental health side effects if you want to read more before your consultation.

You can report any suspected side effect (serious or not) via the MHRA Yellow Card scheme. Doing so helps regulators build the real-world safety picture for everyone who uses these medicines.

Risks specific to your situation: contraindications and interactions

Not every health risk sits in a side-effect table. Some relate to who Mounjaro is not suitable for in the first place. The licence excludes people with a personal or family history of medullary thyroid carcinoma or MEN2 (multiple endocrine neoplasia type 2). A personal history of pancreatitis requires careful prescriber judgement; certain other gastrointestinal conditions, kidney impairment and known hypersensitivity to tirzepatide are all assessed before a prescription is issued.

Mounjaro slows gastric emptying, which affects how quickly the stomach processes food and some oral medicines. Women using oral contraceptives should add a barrier method for the first four weeks of treatment and for four weeks after each dose increase, because absorption of the pill may be reduced, the NHS England guidance on weight-management injections addresses this directly, and it also applies to women on oral HRT who should discuss transdermal alternatives with their doctor.

Surgery is another intersection point: anaesthetists need to know you are taking tirzepatide, as slowed gastric emptying has implications for procedures requiring general anaesthesia. Tell your surgical team well in advance. Pregnancy, breastfeeding and trying to conceive are all situations where Mounjaro is not recommended; treatment should stop before conception, with a wash-out period your prescriber will confirm. The medicine is not licensed for anyone under 18.

Understanding these risks in the context of your own history is precisely what the consultation process is for. A broader look at the full Mounjaro risks and side effects profile, including less common reported events, can help you go into that conversation prepared.

Putting the risk picture in proportion

If you're reading this because you're nervous (or because someone you trust expressed concern) that is a completely reasonable place to be. Mounjaro is a potent medicine, and the questions people ask about its health risks deserve straight answers rather than reassurance dressed up as fact.

What the evidence actually shows is that serious adverse events are uncommon in the trial populations and that the regulatory agencies in the UK reviewed that evidence in full before granting a licence. The MHRA's ongoing monitoring through the Yellow Card system means the real-world picture continues to be assessed. None of that makes side effects impossible for any individual, and some people do find the early weeks difficult, but it does mean this is a medicine with a well-studied risk profile rather than an unknown one.

The complete Mounjaro side effects guide on this site covers the full frequency breakdown from the trial data. For context on how tirzepatide compares across the evidence base, the Mounjaro overview sets out the licensed indications and clinical trial results. Questions about specific rare risks (including what the evidence does and does not show about thyroid) are covered in the Mounjaro cancer risks guide.

At nume, our prescribers discuss suitability and side effects as a standard part of every consultation, not as a checkbox, but because that conversation is what makes the difference between treatment that works and treatment that harms. Speak to our prescribers if you want to work through your personal risk picture before deciding.